23ANDME HOLDING CO.

(ME)
  Report
Delayed Nasdaq  -  05/18 04:00:00 pm EDT
2.930 USD   -2.66%
05/1223andMe to Report FY2022 Fourth Quarter and Full Year Financial Results
GL
05/1223andMe to Report FY2022 Fourth Quarter and Full Year Financial Results
AQ
04/1323ANDME : Current Report (Form 8-K)
PU
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Business Summary
23andMe Holding Co., formerly VG Acquisition Corp., is a consumer genetics and research company. The Company offers direct-to-consumer genetic testing and personalized information about genetic health risks, ancestry, and traits. The Company operates through two segments: Consumer & Research Services and Therapeutics. Its consumer & research services business segment comprises personal genome service (PGS) and research services. Its PGS provides a suite of genetic reports, including information on genetic ancestral origins, personal genetic health risks, rare carrier conditions to their children, as well as reports on how genetics can impact responses to medications. The Company’s therapeutics segment focuses on drug development for discovering and developing therapies to improve patient lives and includes out-licensing of intellectual property. The Company’s programs across therapeutic areas, include oncology, immunology, neurology, metabolic and cardiovascular diseases.

Number of employees : 566 people.
Sales per Business
2021
Consumer & Research Services243.87100%
Therapeutics0.05-
USD in Million
Sales per region
2021
United States176.1272.2%
United Kingdom49.3920.2%
Canada12.175%
Other Regions6.242.6%
USD in Million
Managers
Name Title Age Since
Anne Wojcicki Chief Executive Officer & Director 47 2006
Steven Schoch Chief Financial & Accounting Officer - 2018
Steve Lemon Vice President-Engineering 58 2010
Joyce Tung Vice President-Research 43 2007
L. Onyejekwe VP-Healthcare Operations & Medical Affairs 46 -
Joseph R. Arron, Dr. Chief Scientific Officer - 2021
D. Wade Walke, Dr. Vice President-Investor Relations 55 2021
Kathy L. Hibbs Secretary, Chief Legal & Regulatory Officer 57 2014
Tracy Keim Vice President-Consumer Marketing & Brand 46 2013
Kenneth J. Hillan, Dr. Head-Therapeutics 60 -
Members of the board
Name Title Age Since
Roelof Frederik Botha Independent Director 47 2021
Patrick Shuao-Fong Chung Independent Director - 2021
Peter Taylor Independent Director 62 2021
Valerie C. Montgomery Rice, Dr. Independent Director 59 2021
Sandra Rae Hernández, Dr. Independent Director 62 2021
Anne Wojcicki Chief Executive Officer & Director 47 2006
Evan M. Lovell Director 50 2021
Richard Scheller Director 67 2021
Equities
Vote QuantityFree-FloatCompany-owned sharesTotal Float
Stock A 1 199,176,879 88,977,190 44.7% 0 0.0% 74.7%
Stock B 10 246,970,302 244,500,599 99.0% 0 0.0%
Shareholders
NameEquities%
Sequoia Capital 14,184,130 6.72%
Sapphire Ventures LLC 5,291,826 2.51%
G Squared 5,113,547 2.42%
The Vanguard Group, Inc. 4,805,140 2.28%
Revelation Capital Management LLC 4,667,736 2.21%
Anne Wojcicki 3,750,581 1.78%
Casdin Capital LLC 1,841,457 0.87%
Altimeter Capital Management LP 1,652,021 0.78%
ACATIS Investment Kapitalverwaltungsgesellschaft mbH 1,500,219 0.71%
TOMS Capital Investment Management LP 1,500,000 0.71%
Brand Portfolio
In partnership withAllbrands.markets
More brands of 23andMe Holding Co.